Integrated pharmaceutical company Jubilant Life Sciences reported a 25% year-on-year jump in net sales at Rs 1,087 crore for the three months ended December 31, 2011.
The company witnessed robust growth across its business verticals.
"This strong growth was driven by good volumes from increased capacities and margin improvement in products and services business," Shyam S Bhartia, CMD and Hari S Bhartia, co-chairman and MD of Jubilant Life Sciences said.
After accounting for exceptional items of Rs 155 crore, the company reported loss after tax and minority interest of Rs 78 crore. However, normalised profit-after-tax stood at Rs 77 crore for the quarter.